ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. CSPC Pharmaceutical Group's annualizedNet Income for the quarter that ended in Dec. 2025 was €180 Mil.
CSPC Pharmaceutical Group's average Total Assets over the quarter that ended in Dec. 2025 was €5,662 Mil. Therefore, CSPC Pharmaceutical Group's annualized ROA % for the quarter that ended in Dec. 2025 was 3.18%.
The historical rank and industry rank for CSPC Pharmaceutical Group's ROA % or its related term are showing as below:
FRA:CVGU'
s ROA % Range Over the Past 10 Years
Min: 7.25 Med: 14.84 Max: 18.84
Current: 7.25
During the past 13 years, CSPC Pharmaceutical Group's highest ROA % was 18.84%. The lowest was 7.25%. And the median was 14.84%.
FRA:CVGU's ROA % is ranked better than 73.36% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 2.685
vs FRA:CVGU: 7.25
CSPC Pharmaceutical Group (FRA:CVGU) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, CSPC Pharmaceutical Group's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSPC Pharmaceutical Group ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CSPC Pharmaceutical Group's ROA % distribution charts can be found below:
* The bar in red indicates where CSPC Pharmaceutical Group's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
CSPC Pharmaceutical Group (FRA:CVGU) has a ROA % of 3.18% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on CSPC Pharmaceutical Group and its competitors. This is 79% below median its historical median of 14.84. Over the past decade, CSPC Pharmaceutical Group's ROA % has ranged from 7.25 to 18.84. According to the industry distribution chart, CSPC Pharmaceutical Group ranks #268 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 26.6%.
Is CSPC Pharmaceutical Group's ROA % too high?
CSPC Pharmaceutical Group's current ROA % of 3.18% is 79% below median its 10-year median of 14.84. Over the past 10 years, this metric has ranged from a low of 7.25 to a high of 18.84. The Drug Manufacturers industry median ROA % is 2.69. CSPC Pharmaceutical Group's value of 3.18% is 18.4% above this industry median. Based on the distribution chart, CSPC Pharmaceutical Group ranks #268 out of 1006 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, CSPC Pharmaceutical Group has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does CSPC Pharmaceutical Group's ROA % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, CSPC Pharmaceutical Group ranks #268 out of 1006 companies for ROA %. This puts CSPC Pharmaceutical Group in the upper half of its industry. The industry median ROA % is 2.69. CSPC Pharmaceutical Group's value of 3.18% is 18.4% above this benchmark. Historically, CSPC Pharmaceutical Group's own ROA % has ranged from 7.25 to 18.84 over the past decade. While the company's 10-year median is 14.84 vs. the industry median of 2.69, CSPC Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.69, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CSPC Pharmaceutical Group's current ROA % of 3.18% is 18.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on CSPC Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CSPC Pharmaceutical Group's current ROA % is 3.18%, which is 79% below median its own 10-year median of 14.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSPC Pharmaceutical Group stock overvalued right now?
CSPC Pharmaceutical Group (FRA:CVGU) has a current ROA % of 3.18%. The stock's GF Value™ is €2.52, compared to a current price of €2.58 — trading 2.4% above its estimated fair value. The current ROA % is 3.18%, which is 79% below median its 10-year median of 14.84 and 18.4% above the Drug Manufacturers industry median of 2.69. CSPC Pharmaceutical Group's overall GF Score™ is 88/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For CSPC Pharmaceutical Group (FRA:CVGU), the current ROA % is 3.18% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSPC Pharmaceutical Group (FRA:CVGU) Overvalued in 2026?
Based on GuruFocus' analysis, CSPC Pharmaceutical Group stock appears to be overvalued.
The current stock price of €2.58 is trading 2.4% above its estimated GF Value™ of €2.52.
Key valuation signals for FRA:CVGU:
ROA %: 3.18% (79% below median its 10-year median of 14.84)
GF Value™: €2.52 vs. price of €2.58 (2.4% above fair value)
Industry Position: 18.4% above the Drug Manufacturers median (#268 of 1006)
No single metric tells the full story. See the FRA:CVGU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSPC Pharmaceutical Group LTD is engaged in the manufacture and sale of pharmaceutical products. The group's segments include: Finished drugs, consisting research and development, manufacture and sale of pharmaceutical products and license fee income; Bulk products, that manufacture and sale of vitamin C, and antibiotic products in bulk powder form; and Functional food and others, that manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. It derives maximum revenue from Finished Products segments. Geographically, the company operates in Chinese Mainland, which Chinese Mainland generates maximum revenue; Other Asian regions; Europe; North America; and Others.
88GF Score
Get the complete analysis for FRA:CVGU
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:CVGU has been successfully added to your 
